Voltar à classificação

The Cooper Companies, Inc. (COO)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

57

Preço

$73.38

Capitalização de Mercado

-

Parte 1 · Quanto vale a empresa

Visão Geral

Cooper Companies makes two very different kinds of medical products under one roof: contact lenses, sold through eye-care professionals to people who need vision correction, and instruments and devices used in women's health and fertility clinics — from surgical tools to the equipment IVF labs use to handle embryos. The two businesses share little beyond a corporate parent and a fiscal calendar.

Como gera receita

The lens business is a recurring-purchase model: contact lenses wear out and are reordered regularly, so once a patient is fitted with a brand, replacement sales tend to continue for years. The surgical and fertility business instead sells instruments, disposable devices and lab equipment to clinics and hospitals — some of it capital equipment bought once, some of it consumables reordered with each procedure. Growth in each half of the company depends on different things: population trends in vision correction for one, and clinic capacity and IVF cycle volumes for the other.

Receita por segmento

CooperVision67%

Soft contact lenses, including daily-disposable and specialty lenses that slow the progression of myopia in children.

CooperSurgical33%

Surgical instruments and devices for women's health, plus lab equipment and consumables used in fertility clinics for IVF.

Vantagem competitiva

Custos de mudança · Estreita

A patient fitted and comfortable with a specific contact lens rarely switches brands on their own initiative, and an eye-care professional who has standardized on a fitting set has a mild reason to keep prescribing it. Neither habit is unbreakable: a competing lens of similar quality, or a clinic's own procurement decision, can still displace it.

O que impulsiona a procura

Defensivo

Vision correction is an ongoing need regardless of the economy, which supports the lens business through downturns. The fertility side is more sensitive to discretionary spending and to clinics' own capital budgets: equipment purchases can be postponed when clinics turn cautious, even if underlying procedure demand holds up.

Principais riscos

  • Competition from larger diversified companies — In women's health and fertility, CooperSurgical competes against much larger medical-device companies with broader product lines and greater resources, which can give them an edge in marketing and bundled deals.
  • Reimbursement and pricing pressure — Changes in third-party coverage and reimbursement, and pricing pressure from competitors, can reduce demand or margins on both contact lenses and medical devices.
  • Clinic capital spending cycles — Fertility clinics have shown caution in equipment purchases in soft periods, which slows CooperSurgical's capital-equipment sales even when procedure volumes are stable.

Os argumentos a favor

Buyers argue that steady population growth in myopia and an ageing population needing vision correction give CooperVision durable demand, that specialty myopia-control lenses carry better pricing than commodity lenses, and that CooperSurgical's fertility business benefits from a long-term rise in IVF procedure volumes.

Os argumentos contra

Sellers fear that contact lenses are a largely commoditized product exposed to pricing pressure from larger competitors, that combining two unrelated businesses under one roof makes capital allocation harder to judge from outside, and that fertility clinics' capital spending can stay soft for longer than expected.

Written by the editors, published on 18 de agosto de 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balanço & Liquidez

Receita

$4.23B

Últimos 12 meses (até 30/04/2026)

Resultado Líquido

$236M

Últimos 12 meses (até 30/04/2026)

Fluxo de Caixa Livre

$434M

Capital Próprio Total

$8.24B

Passivo Total

$4.16B

Rácio de Liquidez

1.27

Cobertura de Juros

5.35

Dívida/EBITDA

2.89

Resultados Por Ação

Receita & Resultado Líquido

Fluxo de Caixa Livre

Decomposição dos Resultados

Demonstração histórica

Margens ao longo do tempo

A dívida ao longo do tempo

Quanto pesa a dívida

Grelha do crescimento

Crescimento — Receitas

Estimativa de Valor Justo

Sobrevalorizada

Valor Justo

$51.44

Preço Atual

$73.38

Margem de Segurança

-42.6%

Intervalo de Valor Justo

$33.44 - $69.44

Métodos de Estimativa

Analyst Target:$81.50
DCF:$62.70
PE-based:$17.49
Graham Growth:$28.14
EPV:$22.56
Consenso dos Analistas:Comprar (13B / 10H / 0S)
Última Surpresa de Resultados:+9.30%

Métricas de Avaliação

Rácio P/E

64.79

ROE

4.6%

Rácio P/B

1.79

P/FCF

25.96

Margem Bruta

65.5%

ROIC

3.7%

Radar de Rentabilidade

Value Creation (Economic Moat)

ROIC

3.7%

WACC

7.9%

ROIC − WACC

-4.2 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Critérios de Análise Fundamental

Aprovado (18)

  • EPS shows upward trend
  • Price CAGR 5.71%
  • Gross Margin 65.5%
  • P/FCF 25.96
  • P/B Ratio 1.79
  • Debt/Equity ratio
  • Operating Margin 11.8%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Revenue Growth 5Y 11.0%
  • Analyst Consensus 57% Buy
  • Earnings Surprise avg 4.8%
  • Earnings Quality (OCF/NI) 4.04
  • Share Dilution 0.2%
  • Piotroski F-Score 6/9

Reprovado (9)

  • EPS CAGR 1.63%
  • ROIC 3.7%
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 2.8%
  • PEG Ratio 6.85
  • Net Margin Trend 5.6% vs 10.4%

Indisponível (1)

  • Dividend Payout NaN%

Piotroski F-Score

6/9

Sinais mistos: algumas áreas requerem atenção

score
criteria

Qualidade dos Resultados

4.04

Alta qualidade: resultados respaldados por caixa

Diluição de Ações

0.2%

Número de ações estável

Governação

Equipa Executiva

NomeCargoIdade
Mr. Albert G. White IIIPresident, CEO & Non-Independent Director55
Mr. Daniel G. McBride Esq.Executive VP, COO General Counsel & Secretary61
Ms. Holly R. SheffieldPresident of CooperSurgical, Inc.54
Mr. Gerard H. Warner IIIPresident of CooperVision, Inc.60
Mr. Kim DuncanVice President of Investor Relations & Risk Management-

Risco de Auditoria

10

Risco do Conselho

3

Risco de Remuneração

9

Risco dos Direitos dos Acionistas

3

Parte 2 · O preço e o momento de entrar

Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.

Latest News

Recent headlines for COO, sourced from Markets Gazette.

  • 6/4/2026NEUTRAL
    Full Transcript: Cooper Companies Q2 2026 Earnings Call

    The Cooper Companies (COO) released its Q2 2026 earnings call transcript. While the transcript itself is a factual record of the discussion, it does not contain immediate financial results or forward-looking guidance that would directly impact the stock price. Investors will need to analyze the content of the call, including management's commentary on performance, market conditions, and future outlook, to derive actionable insights. The transcript serves as a source document for deeper fundamental analysis rather than an immediate trading signal.

  • 3/5/2026NEUTRAL
    Cooper (COO) Q1 2026 Earnings Call Transcript

    The Q1 2026 earnings call transcript for Cooper Industries plc (COO) has been released. This document provides details on financial performance, business strategies, and future outlook. While specific figures are not available in this summary, earnings call transcripts are crucial for investors to assess a company's financial health, understand challenges and opportunities, and gain insights into future guidance. A thorough analysis of this transcript could reveal signals of growth or slowdown.

  • 3/5/2026NEUTRAL
    Cooper Companies Earnings Review: Q1 Summary

    Cooper Companies Inc. released its first-quarter results, showing performance in line with analyst expectations. Revenue stood at $920 million, up 6% year-over-year, while adjusted earnings per share came in at $3.80, matching the consensus. The Vision Care division led growth with a 7% increase, while the Women's Health division saw a 5% rise. Guidance for the second quarter was reaffirmed, indicating a stable outlook. For investors, the news confirms the resilience of Cooper Companies' business model, but without any surprises to trigger significant stock movement.

via Markets Gazette